Posted by Michael Wonder on 20 Nov 2021
BioNTech receives FDA fast track designation for its FixVac candidate BNT111 in advanced melanoma
19 November 2021 - BioNTech today announced that the U.S. FDA granted fast track designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma.
BNT111 is the lead product candidate from BioNTech’s fully owned FixVac platform that utilises a fixed combination of mRNA-encoded, tumour-associated antigens aiming to trigger a strong and precise immune response against cancer.
